Etsushi Yoshikawa
Scientist Astellas Pharma
Seminars
Tuesday 9th March 2027
Evaluating the Conjugatability of ADC Drug-Linker Impurities to Develop Process & Impurity Control Strategies
2:45 pm
- Highlighting the importance of evaluating the “conjugatability” of drug linker-derived impurities
- Demonstrating the use of LC-MS/MS and derivatization to efficiently assess impurity conjugatability without full structural identification
- Illustrating how conjugatability assessment can provide scientific insights to develop process optimisation and impurity control
